Risk biomarkers enable precision in public health.

Precision medicine uses biomarkers to diagnose disease. However, they can also be used to measure risk of disease. Thus, biomarkers herald a new addition to public health - Precision Public Health. We examine the implications. Risk biomarkers are identified by analyzing population cohorts. They constitute risk factors in mathematical 'Disease Risk Models'. The risk may be fixed as in a genetic biomarker or variable as in some protein biomarkers. They help monitor current risk of disease in an individual, thereby aiding efforts to reduce risk. In the UK, the NHS Health Check system is a universal system for assessing risk and for risk reduction. The system can now make use of modern biomarkers once appropriate infrastructure and governance are in place.

[1]  E. Shirtcliff,et al.  Neighborhood disorder and telomeres: connecting children's exposure to community level stress and cellular response. , 2013, Social science & medicine.

[2]  N. Cook.  Statistical evaluation of prognostic versus diagnostic models: beyond the ROC curve. , 2008, Clinical chemistry.

[3]  G. Laverack.  Health Promotion Practice: Building Empowered Communities , 2007 .

[4]  J. Emery,et al.  Risk prediction tools for cancer in primary care , 2015, British Journal of Cancer.

[5]  F. Lung,et al.  Older adults with higher income or marriage have longer telomeres , 2012, Age and ageing.

[6]  A. Baccarelli,et al.  The Role of DNA Methylation in Cardiovascular Risk and Disease: Methodological Aspects, Study Design, and Data Analysis for Epidemiological Studies. , 2016, Circulation research.

[7]  Theo Stijnen,et al.  Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. , 2010, Archives of general psychiatry.

[8]  T. Ideker,et al.  Genome-wide methylation profiles reveal quantitative views of human aging rates. , 2013, Molecular cell.

[9]  R. Mayeux,et al.  Association of shorter leukocyte telomere repeat length with dementia and mortality. , 2012, Archives of neurology.

[10]  Gareth Ambler,et al.  How to develop a more accurate risk prediction model when there are few events , 2015, BMJ : British Medical Journal.

[11]  Martin Yuille,et al.  The UK DNA banking network: a “fair access” biobank , 2009, Cell and Tissue Banking.

[12]  M. Lawera.  Predictive inference : an introduction , 1995 .

[13]  W. Riley,et al.  Precision Public Health for the Era of Precision Medicine. , 2016, American journal of preventive medicine.

[14]  Richard L. Smith,et al.  PREDICTIVE INFERENCE , 2004 .

[15]  C. Gieger,et al.  DNA methylation and body-mass index: a genome-wide analysis , 2014, The Lancet.

[16]  P. Kopelman.  Health risks associated with overweight and obesity , 2007, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[17]  Paul C. D. Johnson,et al.  Accelerated Telomere Attrition Is Associated with Relative Household Income, Diet and Inflammation in the pSoBid Cohort , 2011, PloS one.

[18]  Jonathan A. Heiss,et al.  DNA methylation signatures in peripheral blood strongly predict all-cause mortality , 2017, Nature Communications.

[19]  C. Wild.  Complementing the Genome with an “Exposome”: The Outstanding Challenge of Environmental Exposure Measurement in Molecular Epidemiology , 2005, Cancer Epidemiology Biomarkers & Prevention.

[20]  Rodney X. Sturdivant,et al.  Applied Logistic Regression: Hosmer/Applied Logistic Regression , 2005 .

[21]  W. Willett,et al.  Harvard Report on Cancer Prevention Volume 4: Harvard Cancer Risk Index , 2004, Cancer Causes & Control.

[22]  G. Collins,et al.  Identifying patients with undetected pancreatic cancer in primary care: an independent and external validation of QCancer(®) (Pancreas). , 2013, The British journal of general practice : the journal of the Royal College of General Practitioners.

[23]  Elisabetta Vaudano,et al.  The Innovative Medicines Initiative: a Public Private Partnership Model to Foster Drug Discovery , 2013, Computational and structural biotechnology journal.

[24]  R. West,et al.  A randomized controlled trial of a "buddy" systems to improve success at giving up smoking in general practice. , 1998, Addiction.

[25]  E. Welch,et al.  Financial Sustainability of Biobanks: From Theory to Practice. , 2017, Biopreservation and biobanking.

[26]  K. Khunti,et al.  Evaluation of community provision of a preventive cardiovascular programme - the National Health Service Health Check in reaching the under-served groups by primary care in England: cross sectional observational study , 2017, BMC Health Services Research.

[27]  Andrew P. Feinberg,et al.  Genome-scale approaches to the epigenetics of common human disease , 2009, Virchows Archiv.

[28]  H. Brenner,et al.  DNA methylation changes of whole blood cells in response to active smoking exposure in adults: a systematic review of DNA methylation studies , 2015, Clinical Epigenetics.

[29]  Tom R. Gaunt,et al.  Epigenome-wide association of DNA methylation markers in peripheral blood from Indian Asians and Europeans with incident type 2 diabetes: a nested case-control study. , 2015, The lancet. Diabetes & endocrinology.

[30]  R. West,et al.  Randomized controlled trial of a social support ('buddy') intervention for smoking cessation. , 2006, Patient education and counseling.

[31]  Andrea Ganna,et al.  5 year mortality predictors in 498 103 UK Biobank participants: a prospective population-based study , 2015, The Lancet.

[32]  A. D. Diez Roux,et al.  Neighborhood characteristics and leukocyte telomere length: the Multi-Ethnic Study of Atherosclerosis. , 2014, Health & place.

[33]  E. Lau,et al.  Maternal Weight Gain in Pregnancy and Risk of Obesity among Offspring: A Systematic Review , 2014, Journal of obesity.

[34]  YuilleModerator Martin,et al.  Financial Sustainability of Biobanks: From Theory to Practice. , 2017 .

[35]  G. Poste.  Bring on the biomarkers , 2011, Nature.

[36]  F. Collins,et al.  A vision for the future of genomics research , 2003, Nature.